Vancouver, British Columbia –TheNewswire –May 7, 2025– MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a pioneering clinical-stage biopharmaceutical company dedicated to developing novel and effective mental health treatments, has today issued Restricted Stock Units (RSUs) to certain directors and individuals that work for the Company.
On May 2, 2025, the Company’s Board of Directors approved the issuance of an aggregate of 8,000,000 Restricted Stock Units (“RSUs”) to two of its independent directors in lieu of cash compensation for their service on the Board. A further 27,004,730 RSUs were issued to twelve individual staff and contractors of the Company in lieu of cash compensation. The RSUs vest upon the occurrence of a “Vesting Event” as defined in the applicable RSU grant agreements. Upon vesting, one share in the capital of the Company will be issued for each vested RSU held.
“Securing the commitment and services of talented people is of utmost importance to the success of the company as it enters its next stage of clinical trials” said Justin Hanka, Chief Executive Officer of MindBio Therapeutics. “The issuing of RSUs to the dedicated individuals that work for the Company, who have worked diligently for long periods without any compensation, aligns their interests with the Company and its shareholders and is demonstrative of the Company’s commitment to creating a successful future.”
MindBio’s innovative approach to scaling the regulated take-home use of psychedelic medicines in advanced stage clinical trials, is poised to redefine the treatment landscape for mental health disorders. By prioritizing accessibility and affordability, the company aims to deliver a globally scalable solution that addresses the systemic challenges of traditional mental health interventions and avoid the clinic based limitations of psychedelic medicine treatments.
MindBio invites stakeholders, partners, and the global community to join in supporting its vision for a brighter future in mental health. For more information about MindBio Therapeutics, MB22001, or opportunities for collaboration, please visit www.mindbiotherapeutics.com.
About MindBio Therapeutics
MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6) is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, focused on developing novel psychedelic-based medicines for mental health disorders. With a commitment to scientific rigor and patient accessibility, MindBio is pioneering the use of regulated, take-home use of psychedelic medicines in clinical trials to provide safe, effective, and scalable treatments for conditions such as depression, anxiety, and other psychological challenges. The company’s mission is to improve global mental health outcomes through innovative, evidence-based treatment that is accessible and affordable.